...
首页> 外文期刊>International Journal of Vascular Medicine >Diabetes Mellitus and Cardiovascular Prevention: The Role and the Limitations of Currently Available Antiplatelet Drugs
【24h】

Diabetes Mellitus and Cardiovascular Prevention: The Role and the Limitations of Currently Available Antiplatelet Drugs

机译:糖尿病和心血管疾病的预防:目前可用的抗血小板药物的作用和局限性

获取原文
           

摘要

Diabetes mellitus (DM) is associated with macrovascular and microvascular complications. Platelets have a “key role” in atherogenesis and its thrombotic complications in subjects with DM. Moreover, the concomitant presence of multiple “classical” cardiovascular risk factors in diabetic subjects contributes to enhanced atherothrombotic risk. Antiplatelet agents are effective in primary and secondary prevention of arterial thrombosis (cardiovascular events, ischaemic stroke, and peripheral arterial occlusive disease). The role of chronic administration of antiplatelet drugs in primary prevention of arterial vascular events is known to be less clear than in secondary prevention, and, also in diabetic patients, the decision to give primary prophylaxis should be taken on an individual-patient basis, after a careful evaluation of the balance between the expected benefits and the risk of major bleedings. Although, currently, treatment has proven useful in reducing vascular events, diabetic patients continue to have a higher risk of adverse cardiovascular events compared with those in nondiabetic patients. This paper reviews the role of currently available antiplatelet drugs in primary and secondary prevention of vascular events in diabetic patients and the limitations of these drugs, and it discusses the role of novel and more potent antiplatelets and of new agents currently under clinical development.
机译:糖尿病(DM)与大血管和微血管并发症相关。血小板在糖尿病患者的动脉粥样硬化及其血栓并发症中具有“关键作用”。此外,糖尿病患者同时存在多种“经典”心血管危险因素也导致动脉粥样硬化血栓形成风险增加。抗血小板药可有效预防一级和二级动脉血栓形成(心血管事件,缺血性中风和外周动脉闭塞性疾病)。众所周知,长期给予抗血小板药物在一级预防血管血管事件中的作用不如在二级预防中明确,而且在糖尿病患者中,应在个体患者的基础上决定是否进行一级预防仔细评估预期收益与大出血风险之间的平衡。尽管目前已证明治疗可用于减少血管事件,但与非糖尿病患者相比,糖尿病患者继续具有较高的不良心血管事件风险。本文综述了目前可用的抗血小板药物在糖尿病患者血管事件的一级和二级预防中的作用以及这些药物的局限性,并讨论了新型,更有效的抗血小板药物和目前正在临床开发中的新药物的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号